CoChat

Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells

Open access
Perry, John M., Tao, Fang, Roy, Anuradha, Lin, Tara, He, Xi C., Chen, Shiyuan, Lu, Xiuling, Nemechek, Jacqelyn, Ruan, Linhao, Yu, Xiazhen, Dukes, Debra, Moran, Andrea, Pace, Jennifer, Schroeder, Kealan, Zhao, Meng, Venkatraman, Aparna, Qian, Pengxu, Li, Zhenrui, Hembree, Mark, Paulson, Ariel, He, Zhiquan, Xu, Dong, Tran, Thanh-Huyen, Deshmukh, Prashant, Nguyen, Chi Thanh, Kasi, Rajeswari M., Ryan, Robin, Broward, Melinda, Ding, Sheng, Guest, Erin, August, Keith, Gamis, Alan S., Godwin, Andrew, Sittampalam, G. Sitta, Weir, Scott J., Li, Linheng · 2020 · Nature Cell Biology
Cited by 136

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Leukaemia stem cells (LSCs) underlie cancer therapy resistance but targeting these cells remains difficult. The Wnt–β-catenin and PI3K–Akt pathways cooperate to promote tumorigenesis and resistance to therapy. In a mouse model in which both pathways are activated in stem and progenitor cells, LSCs expanded under chemotherapy-induced stress. Since Akt can activate β-catenin, inhibiting this interaction might target therapy-resistant LSCs. High-throughput screening identified doxorubicin (DXR) as an inhibitor of the Akt–β-catenin interaction at low doses. Here we repurposed DXR as a targeted inhibitor rather than a broadly cytotoxic chemotherapy. Targeted DXR reduced Akt-activated β-catenin levels in chemoresistant LSCs and reduced LSC tumorigenic activity. Mechanistically, β-catenin binds multiple immune-checkpoint gene loci, and targeted DXR treatment inhibited expression of multiple immune checkpoints specifically in LSCs, including PD-L1, TIM3 and CD24. Overall, LSCs exhibit distinct properties of immune resistance that are reduced by inhibiting Akt-activated β-catenin. These findings suggest a strategy for overcoming cancer therapy resistance and immune escape. Targeting resistant stem cells in leukaemia, Perry et al. show that doxorubicin at low doses decreases Akt-mediated β-catenin activity, downregulates expression of multiple immune-checkpoint genes and dampens tumorigenesis of leukaemia stem cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41556-020-0507-y

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 136

Metadata

Authors
Perry, J. M., Tao, F., Roy, A., Lin, T., He, X. C., Chen, S., Lu, X., Nemechek, J., Ruan, L., Yu, X., Dukes, D., Moran, A., Pace, J., Schroeder, K., Zhao, M., Venkatraman, A., Qian, P., Li, Z., Hembree, M., Paulson, A., He, Z., Xu, D., Tran, T.-H., Deshmukh, P., Nguyen, C. T., Kasi, R. M., Ryan, R., Broward, M., Ding, S., Guest, E., August, K., Gamis, A. S., Godwin, A., Sittampalam, G. S., Weir, S. J., & Li, L.
Venue
Nature Cell Biology
Published
2020-04-20
Volume
22
Issue
6
Pages
689-700
ISSN
  • 1465-7392 (ISSN-L)
  • 1476-4679
OpenAlex
W3016978893
Cited by
136
References
18
FWCI
5.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells. https://app.cochat.ai/papers/10.1038/s41556-020-0507-y
The paper
Perry, J. M., Tao, F., Roy, A., Lin, T., He, X. C., Chen, S., Lu, X., Nemechek, J., Ruan, L., Yu, X., Dukes, D., Moran, A., Pace, J., Schroeder, K., Zhao, M., Venkatraman, A., Qian, P., Li, Z., Hembree, M., . . . Li, L. (2020). Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nature Cell Biology. https://doi.org/10.1038/s41556-020-0507-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.